Q-omics provides the consensus-scored EIF5B profile across patient tissues and cancer cell-line models. EIF5B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EIF5B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, EIF5B protein abundance shows 27,041 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where EIF5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF5B survival associations across molecular data types. EIF5B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF5B RNA expression–survival associations across cancer types. High EIF5B expression shows unfavorable associations in MESO, ACC, LIHC, KICH, KIRP and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for EIF5B RNA expression.
This table summarizes EIF5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for EIF5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF5B shows higher tumor expression in HNSC, LIHC, KIRP, LUAD, LUSC and BRCA. The HNSC box plot shows higher EIF5B RNA expression in tumor versus normal tissue (log2 FC = +0.889, t-test p < 0.001).
This table shows molecular features associated with EIF5B in patient tissues and cancer cell lines. In patient samples, EIF5B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, EIF5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
